The last five years has been a unique time period for the global biotech and pharmaceutical landscape, encompassing the COVID-19 pandemic and all the challenges and opportunities it created. Clinical trials have seen continued growth, with uneven geographical distribution.
In this whitepaper, GlobalData and Novotech analyse key data from 2017-2022, shedding light on the key trends affecting clinical trials. Understand the effects of the COVID-19 pandemic and other macro events, including an impending recession. Discover where the biggest growth opportunities are to be found.
APAC emerges as an outliner when it comes to trial numbers, growth and density. Biotech and pharmaceutical companies should become familiar with the features that could make APAC the primary trial hub of the future.